Biochemical evaluation of intracerebroventricular rhNAGLU-IGF2 enzyme replacement therapy in neonatal mice with Sanfilippo B syndrome

Keyphrases

• Neonatal Mice 100%
• Enzyme Replacement Therapy 100%
• Sanfilippo Syndrome 100%
• Biochemical Assessment 100%
• Insulin-like Growth Factor 2 (IGF2) 100%
• MPS IIIB 100%
• N-acetylglucosaminidase 60%
• Activity Level 40%
• Heparan Sulfate 40%
• β-hexosaminidase 40%
• Liver 20%
• Mouse Model 20%
• Effective Treatment 20%
• Potential Gains 20%
• Brain Tissue 20%
• Early Treatment 20%
• Fusion Protein 20%
• Therapeutic Effect 20%
• Canine Model 20%
• Liver Tissue 20%
• Neurological Deterioration 20%
• Mucopolysaccharidosis IIIB 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Replacement Therapy 100%
• Syndrome 100%
• Acetylglucosaminidase 100%
• Heparan Sulfate 66%
• Beta N Acetylhexosaminidase 66%
• Mouse Model 33%
• Mucopolysaccharidosis 33%
• Sanfilippo Syndrome 33%
• Therapeutic Effect 33%
• Preclinical Study 33%
• Canine Model 33%
• Chimeric Protein 33%

Medicine and Dentistry

• Enzyme Replacement Therapy 100%
• Acetylglucosaminidase 100%
• Single Drug Dose 66%
• Heparan Sulfate 66%
• Beta N Acetylhexosaminidase 66%
• Clinical Study 33%
• Lifespan 33%
• Mucopolysaccharidosis 33%
• Sanfilippo Syndrome 33%
• Therapy Effect 33%
• Brain Tissue 33%
• Liver Tissue 33%
• Chimeric Protein 33%